GRI Bio, Inc. CEO Marc Hertz Discusses Advancements in NKT Cell Modulators for IPF in Recent Virtual Investor Segment

Quiver QuantitativeMar 18 09:13 ET

12 Health Care Stocks Moving In Monday's Intraday Session

BenzingaMar 17 13:05 ET

GRI Bio Reports As Of December 31, 2024, The Company Had Cash And Cash Equivalents Of ~$5M; Cash Runway Expected To Fund Operations Into Q2 2025, Including Interim Data Readout From GRI-0621

BenzingaMar 17 08:13 ET

Express News | GRI Bio Inc - Cash Runway Expected to Fund Operations Into Q2 2025

ReutersMar 17 08:05 ET

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

GRI BIOMar 17 00:00 ET

GRI Bio | 10-K: FY2024 Annual Report

SECMar 14 17:01 ET · Announcements